Ted Bird, Chief Strategy Officer of Dymicron was selected as an Innovation leader to present at the #LSIUSA22 Emerging Medtech Summit.
Ted is passionate about innovative medical device technology which provides meaningful improvements to patient lives. He is a spine industry expert, with over 30 years of global commercial and executive leadership experience with market leading companies including Medtronic, JNJ, Orthofix, ApiFix and Titan Spine.
Dymicron is advancing a new artificial cervical total disc replacement implant made from polycrystalline diamond — which generates no detectable wear debris. The unique biomechanical design of the Triadyme-C disc also replicates the natural motion and mobility of a normal disc.
Dymicron Inc. is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. A copy of the Final Offering Circular that forms a part of the Offering Statement may be obtained from: Dymicron Inc.